Cargando…
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Classic tumor therapy, consisting of cytotoxic agents and/or targeted therapy, has not overcome therapeutic limitations like poor risk genetic parameters, genetic heterogeneity at different metastatic sites or the problem of undruggable targets. Here we summarize data and trials principally followin...
Autores principales: | Heudobler, Daniel, Rechenmacher, Michael, Lüke, Florian, Vogelhuber, Martin, Klobuch, Sebastian, Thomas, Simone, Pukrop, Tobias, Hackl, Christina, Herr, Wolfgang, Ghibelli, Lina, Gerner, Christopher, Reichle, Albrecht |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279883/ https://www.ncbi.nlm.nih.gov/pubmed/30546308 http://dx.doi.org/10.3389/fphar.2018.01357 |
Ejemplares similares
-
Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction
por: Heudobler, Daniel, et al.
Publicado: (2019) -
Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis
por: Heudobler, Daniel, et al.
Publicado: (2021) -
Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018) -
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia
por: Hart, Christina, et al.
Publicado: (2015) -
A Computational Model of Tumor Growth and Anakoinosis
por: Pantziarka, Pan, et al.
Publicado: (2019)